Printer Friendly

Gannett Co names Paul Bascobert as president and CEO.

Global Banking News-August 6, 2019-Gannett Co names Paul Bascobert as president and CEO

(C)2019 ENPublishing -

Gannett Co Inc (NYSE: GCI), a digitally focused media and marketing solutions company, announced on Monday the appointment of Paul Bascobert as president, CEO and a member of the company's board of directors, with immediate effect.

Bascobert, who joins Gannett with more than two decades of management experience across media, marketing and technology, most recently served as president of XO Group, from 2016 until its sale to Permira Equity in 2019.

Prior to that, he served as president of Local Businesses at Yodle, a local internet marketing and advertising solutions provider for small businesses, from 2014 to 2016. Before that, he held leadership roles at multiple media companies, including Bloomberg LP, where he served as COO of its Media Group and president of Bloomberg Businessweek, and at Dow Jones & Co, where he served as chief marketing officer across its consumer products, including The Wall Street Journal, Barron's and MarketWatch.

Earlier, Bascobert co-founded Vertex Partners, which leveraged data analytics to drive sales and product strategy within the pharmaceutical and media industries. Bascobert began his career as an engineer with General Motors and Whirlpool Corporation.

Gannett Co's brands include USA TODAY NETWORK, with the iconic USA TODAY, and over 100 local media brands, digital marketing services companies ReachLocal, WordStream and SweetIQ, as well as UK media company Newsquest.

((Distributed via M2 Communications -

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Global Banking News (GBN)
Date:Aug 6, 2019
Previous Article:Pernod Ricard acquires Firestone & Robertson Distilling Co in Texas, US.
Next Article:Regeneron Pharmaceuticals Inc announces EC marketing approval for Dupixent (dupilumab) for moderate-to-severe atopic dermatitis.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |